Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Bio-Rad Laboratories, Inc. (BIO)

507.84   2.26 (0.45%) 06-26 19:34
Open: 509.94 Pre. Close: 505.58
High: 511.7091 Low: 502.91
Volume: 166,290 Market Cap: 15,057(M)
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 512.02 - 513.53 513.53 - 515.22
Low: 498.27 - 500.13 500.13 - 502.22
Close: 504.55 - 507.37 507.37 - 510.52

Technical analysis

as of: 2022-06-24 4:38:24 PM
Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time.
Target: Six months: 645.62     One year: 754.08
Support: Support1: 497.04    Support2: 462.6
Resistance: Resistance1: 552.76    Resistance2: 645.62
Pivot: 495.61
Moving Average: MA(5): 486.31     MA(20): 506.75
MA(100): 548.37     MA(250): 658.38
MACD: MACD(12,26): -9.7     Signal(9): -10.4
Stochastic oscillator: %K(14,3): 41.1     %D(3): 26.5
RSI: RSI(14): 51.7
52-week: High: 832.7  Low: 462.6
Average Vol(K): 3-Month: 221 (K)  10-Days: 173 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BIO ] has closed below upper band by 38.5%. Bollinger Bands are 30.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sun, 26 Jun 2022
What is Jake Paul’s boxing record? Age, bio, outcomes for YouTube and boxing personality - Sporting News

Sun, 26 Jun 2022
Sierra Leone's President Julius Maada Bio attends opening ceremony of CHOGM, holds bilateral meetings with leaders of Rwanda, Singapore and Belize - The Patriotic Vanguard

Fri, 24 Jun 2022
'Selfish': Internet Rips Dad Who Bought Car for Stepson Instead of Bio Kids - Newsweek

Thu, 23 Jun 2022
How To Change Your Instagram Bio - Bustle

Wed, 22 Jun 2022
Vibe Bio Launches To Transform Drug Development For Patients With Rare Diseases - Business Wire

Tue, 21 Jun 2022
BIO research outlines importance of accelerated approval pathway -

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Medical Devices
Shares Out. 25 (M)
Shares Float 21 (M)
% Held by Insiders 14.3 (%)
% Held by Institutions 79.3 (%)
Shares Short 408 (K)
Shares Short P.Month 330 (K)

Stock Financials

EPS -3.4
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 340.1
Profit Margin (%) -3.5
Operating Margin (%) 20.6
Return on Assets (ttm) 2.6
Return on Equity (ttm) -1
Qtrly Rev. Growth -3.8
Gross Profit (p.s.) 67.83
Sales Per Share 117.79
EBITDA (p.s.) 29.66
Qtrly Earnings Growth 0
Operating Cash Flow 589 (M)
Levered Free Cash Flow 433 (M)

Stock Valuations

PE Ratio -149.81
PEG Ratio 2
Price to Book value 1.49
Price to Sales 4.31
Price to Cash Flow 21.21

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.